Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Signs Agreement With Paratek For PTK 0796
Novartis has gained exclusive worldwide rights to market PTK 0796 as the potential first once-daily broad-spectrum antibiotic that can be given by intravenous (IV) infusion or oral tablet.
Novartis has gained exclusive worldwide rights to market PTK 0796 as the potential first once-daily broad-spectrum antibiotic that can be given by intravenous (IV) infusion or oral tablet.
Ipsen and Spirogen have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder, SJG-136 (now known as SG2000). The new agreement
Antisoma, following discussions with FDA and trial investigators, plans to amend the primary endpoint in the ACCEDE study of AS1413. The ACCEDE study is an ongoing randomised, controlled
MacuCLEAR and Mystic Pharmaceuticals have announced preliminary results of phase Ib clinical trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). According
Bayer Schering Pharma has reported that it will provide its development candidate florbetaben, a PET (positron emission tomography) tracer, to AC Immune, to support a clinical trial in
BioGaia has entered into an agreement with Pharma Nord, which gives Pharma Nord exclusive rights to sell BioGaia’s Probiotic tablets and drops in Denmark. Reportedly, BioGaia’s probiotic products
Labopharm has reported that its wholly-owned subsidiary, Labopharm Europe has completed a distribution and supply agreement with Grunenthal for its twice-daily tramadol acetaminophen formulation. Under the terms of
Hospira has entered into a business co-operation agreement with South Korea-based Celltrion and Celltrion Healthcare. Under the distribution agreement, the companies would collaborate on manufacturing and supply of
NextPharma has expanded its core capabilities through the addition of clinical trial services at its San Diego, California facility. The company said that these new services mirror NextPharma’s
CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world’s first patented triple-combination cardiovascular polypill. Reportedly, CardioPharma collected data on thousands of patients